Dallas, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) — The global retinal biologics market is projected to grow at a CAGR of 6.5%. Increasing prevalence of retinal disorders such as macular degeneration, diabetic retinopathy, rapidly growing geriatric population along with increase in diabetic population are factors driving the retinal biologics market.
Request for a sample of this research report @ https://www.adroitmarketresearch.com/contacts/request-sample/1841
Global Retinal Biologics Market 2018-2028
Adroit Market Research report on global retinal biologics market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for historic years from 2018 and 2019, with the base year of estimation as 2019 and forecast from 2020 to 2028. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the market based on Porter’s five forces analysis and positions the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global retinal biologics market have been studied in detail.
Diabetic retinopathy and age-related macular degeneration are leading causes of blindness in the Western countries. According to the National Eye Institute (NEI), approximately 2.0 million Americans were affected with age-related macular degeneration in 2010, which is projected to more than double to reach an estimated 5.4 million by 2050. Retinal biologics are widely being adopted in order to treat patients with retinal vein occlusions, age-related macular degeneration, and diabetic retinopathy. Increase in geriatric patient pool susceptible to age-related ophthalmic disorders will further fuel the demand for retinal biologics. Moreover, rapid technological advancements by leading industry players is anticipated to fuel the growth of the market in the future.
Browse Complete Report with Table of Contents @ https://www.adroitmarketresearch.com/industry-reports/retinal-biologics-market
The global retinal biologics market has been segmented based on drug class, application, and region. Based on drug class, the global retinal biologics market is categorized into VEGF antagonists and TNF-a inhibitors. VEGF antagonists segment held for substantial share of the global market in 2019 owing to the therapeutic benefits offered for the treatment of diabetic retinopathy, neovascular aged-related macular degeneration (nAMD), and ischemic retinopathies. Application-wise, the global retinal biologics market is segregated into age-related macular degeneration, diabetic retinopathy, uveitis and others. Diabetic retinopathy is predicted to witness high growth owing to rapidly increasing diabetic population across the globe.
North America dominated the global retinal biologics market in 2019. High prevalence of ophthalmic disorders in the U.S. and Canada, higher adoption of innovative products are key factors likely to drive the growth of the market in the next few years. However, Asia Pacific retinal biologics market is anticipated to grow at a rapid pace over the forecast period owing to presence of large geriatric population, higher incidence of diabetes in India and China will propel the growth of retinal biologics in the region.
Major players operating in the global retinal biologics market include F. Hoffmann-La Roche, Regeneron Pharmaceuticals Inc., AbbVie Inc., MeiraGTx Limited, Oxurion NV, Novartis, Merck & Co., Inc., Allergan, and Santel Pharmaceuticals among others.
Direct purchase the report @ https://www.adroitmarketresearch.com/researchreport/purchase/1841
Key Segments of the Global Retinal Biologics Market
Drug Class Overview, 2018-2028 (USD Million)
- VEGF Antagonists
- TNF-a Inhibitors
Indication Overview, 2018-2028 (USD Million)
- Diabetic Retinopathy
- Macular Degeneration
Regional Overview, 2018-2028 (USD Million)
- North America
- United Kingdom
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- South Africa
- Rest of Middle East & Africa
Table of Contents:
2. Research Methodology
3. Market Outlook
4. Retinal Biologics Market by Drug Class, 2018-2028 (USD Million)
5. Retinal Biologics Market by Application, 2018-2028 (USD Million)
6. Retinal Biologics Market by Region, 2018-2028 (USD Million)
7. Competitive Landscape
8. Company Profiles
Browse Related Reports:
Global Plasma Protease C1 Inhibitor Market Size 2020, By Drug Type (C1-Inhibitors, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist) Dosage Form (Lyophilized, Injectable) Region (North America, Europe, Asia Pacific, South America, Middle East and Africa) and Forecast 2021 to 2028
Global Retinal Implants Market Size 2020, By Device Type (Retina Implant Alpha AMS, Implantable Miniature Telescope, Argus II, Others) Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) and Forecast 2021 to 2028
Global Biologics Market Drivers, Restraints, Potential Growth Opportunities, Product Size, Application Estimation, Vendor Competitive Landscape, Trends and Forecast 2018-2025
Access research repository of Upcoming Reports @ https://adroitmarketresearch.com/upcoming.html
Adroit Market Research is a global business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a market’s size, key trends, participants and future outlook of an industry. We intend to become our clients’ knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code– Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.
Account Manager – Global
3131 McKinney Ave Ste 600
Dallas, TX 75204
Email ID: email@example.com
Phone No.: +1 972-362 -8199
Connect with us: Facebook | Twitter | LinkedIn